Bengaluru: Pandorum Technologies, a biotechnology company pioneering programmable regenerative medicine with operations in India and the United States, has announced the closing of a US$18 million Series B financing round to advance the clinical development of its disease-modifying, tunable, exosome-based therapies, including Kuragenx, while scaling global manufacturing and expanding operations across the U.S., Japan, and the Middle East.
The funding round was led by Protons Corporate, with participation from Galentic Pharma, Ashish Kacholia, Noblevast Advisory and Avinya Fund, Burman Family, and others.
Bandana Kankani, advisor and investor at Pandorum Technologies, guided the transaction, aligning the investment architecture with the company’s value-creation strategy.
Also Read: RDI Fund: INR 1 Lakh Crore Innovation Scheme Enters Execution Phase; TDB, BIRAC Approved as SLFMs
Pandorum Technologies Series B Funding to Accelerate Clinical Development
Founded by Tuhin Bhowmick and Arun Chandru, Pandorum Technologies has developed a proprietary platform combining biology, engineering, and computation to create tunable regenerative exosome therapies that reprogram pathological tissue states such as inflammation and fibrosis toward functional recovery.
“Just like the Ship of Theseus, the human body is constantly being rebuilt. Pandorum focuses on restoring biological memory, redefining regenerative medicine at its core,” said Dr Tuhin Bhowmick, Co-Founder and CEO of Pandorum Technologies.
“Our approach treats tissue health, disease, and degeneration as a navigational challenge within an information-constrained biological landscape,” added Dr. Tuhin.
“This funding would enable us to translate breakthrough science into programmable, disease-modifying therapies, beginning with single-tissue applications and scaling to multi-tissue repair, aligned with Pandorum’s vision – to heal fast and age slow.”
“Congratulations to our team for this achievement. Regenerative medicine, particularly for corneal blindness, is a global necessity that knows no borders,” said co-founder Arun Chandru.
Clinical translation efforts are being led by globally recognized clinicians including Dr. Virender Singh Sangwan (Dr. Shroff’s Charity Eye Hospital, New Delhi), Dr. Shigeru Kinoshita (Kyoto Prefectural University of Medicine, Kyoto), and Dr. Ramez Haddadin and Dr. Satish Nadig (Northwestern Medicine, Chicago).
Also Read: Coalition for Epidemic Preparedness Innovations Renews Engagement Strategy with DBT and BIRAC
Pandorum Technologies has implemented a globally distributed manufacturing strategy, including a CDMO partnership with AGC Biologics (Italy) for the U.S. and European markets, and a strategic collaboration with Nucelion Therapeutics (India), a subsidiary of Bharat Biotech, to support supply across the Asia-Pacific region. The company is also exploring potential partnerships in the Middle East.
The company’s primary focus is on ocular surface diseases, including Stevens–Johnson Syndrome and Neurotrophic Keratitis, for which Kuragenx has received U.S. FDA Orphan Drug Designation.
Beyond ophthalmology, Pandorum is expanding its tunable platform to address inflammatory and degenerative diseases affecting the lung, liver, and nervous systems.
.
